{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:36:56Z","timestamp":1793144216974,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K23DK117014-01"],"award-info":[{"award-number":["1K23DK117014-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F32 DC017342-02"],"award-info":[{"award-number":["F32 DC017342-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K23DK10644805"],"award-info":[{"award-number":["5K23DK10644805"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24DK091417"],"award-info":[{"award-number":["K24DK091417"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1053\/j.ajkd.2019.10.011","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T08:58:31Z","timestamp":1579510711000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma"],"prefix":"10.1053","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Seethapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Strohbehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shveta S.","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary C.","family":"Curhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2019.10.011_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel\u00a0CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.10.011_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1053\/j.ajkd.2019.10.011_bib3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2019.10.011_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1053\/j.ajkd.2019.10.011_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.6004\/jnccn.2018.0073","article-title":"Chimeric antigen receptor T-cell therapy","volume":"16","author":"Ogba","year":"2018","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"7","key":"10.1053\/j.ajkd.2019.10.011_bib6","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy","volume":"11","author":"Ramos","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.ajkd.2019.10.011_bib7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.10.011_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.10.011_bib9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.10.011_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.10.011_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2019.10.011_bib12","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-Cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6295","key":"10.1053\/j.ajkd.2019.10.011_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1053\/j.ajkd.2019.10.011_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41586-018-0499-y","article-title":"A\u00a0homing system targets therapeutic T cells to brain cancer","volume":"561","author":"Samaha","year":"2018","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.ajkd.2019.10.011_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors review-article","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2019.10.011_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.ajkd.2019.10.011_bib17","first-page":"577","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2019.10.011_bib18","article-title":"FDA Briefing Document Oncologic Drugs Advisory Committee Meeting - BLA 125646 Tisagenlecleucel Novartis Pharmaceuticals Corporation","year":"2017","journal-title":"FDA"},{"issue":"5","key":"10.1053\/j.ajkd.2019.10.011_bib19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2019.10.011_bib20","first-page":"3584","article-title":"Risk of hyponatremia and associated clinical characteristics in patients with acute lymphoblastic leukemia after CD19 targeted chimeric antigen receptor (CAR) T-cells","volume":"130","author":"Dixon","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ajkd.2019.10.011_bib21","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ajkd.2019.10.011_bib22","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood.V126.23.3773.3773","article-title":"Addition of fludarabine to cyclophosphamide lymphodepletion improves in\u00a0vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.ajkd.2019.10.011_bib23","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.ajkd.2019.10.011_bib24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2019.10.011_bib25","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2017."},{"issue":"2","key":"10.1053\/j.ajkd.2019.10.011_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ajkd.2019.10.011_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1053\/j.ajkd.2019.10.011_bib28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.ajkd.2019.10.011_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/ken402","article-title":"Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis","volume":"48","author":"Jayachandran","year":"2009","journal-title":"Rheumatology"},{"issue":"4","key":"10.1053\/j.ajkd.2019.10.011_bib30","first-page":"192","article-title":"Cyclophosphamide-induced symptomatic hyponatraemia","volume":"69","author":"Bruining","year":"2011","journal-title":"Neth J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2019.10.011_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and\u00a0chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619311254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619311254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:28:54Z","timestamp":1759462134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619311254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0272638619311254"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.10.011","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}